IBRX stock jumps on progress in NK cell therapy production

Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing engineering programs for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform. The company completed the NK2022 and NK2023 programs, demonstrating that its process for collecting immune cells from blood and converting them into natural killer (NK) cell therapies can be performed safely,...